ID   SMAD3_RAT               Reviewed;         425 AA.
AC   P84025; O09064; O09144; O14510; O35273; Q92940; Q93002; Q9GKR4;
DT   05-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   02-OCT-2024, entry version 176.
DE   RecName: Full=Mothers against decapentaplegic homolog 3;
DE            Short=MAD homolog 3;
DE            Short=Mad3;
DE            Short=Mothers against DPP homolog 3;
DE   AltName: Full=SMAD family member 3;
DE            Short=SMAD 3;
DE            Short=Smad3;
GN   Name=Smad3; Synonyms=Madh3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=8917532; DOI=10.1073/pnas.93.23.12992;
RA   Chen Y., Lebrun J.-J., Vale W.W.;
RT   "Regulation of transforming growth factor beta- and activin-induced
RT   transcription by mammalian Mad proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:12992-12997(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   INTERACTION WITH MEN1.
RX   PubMed=11274402; DOI=10.1073/pnas.061358098;
RA   Kaji H., Canaff L., Lebrun J.J., Goltzman D., Hendy G.N.;
RT   "Inactivation of menin, a Smad3-interacting protein, blocks transforming
RT   growth factor type beta signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:3837-3842(2001).
RN   [4]
RP   INTERACTION WITH CITED2.
RX   PubMed=16619037; DOI=10.1038/sj.onc.1209552;
RA   Chou Y.T., Wang H., Chen Y., Danielpour D., Yang Y.C.;
RT   "Cited2 modulates TGF-beta-mediated upregulation of MMP9.";
RL   Oncogene 25:5547-5560(2006).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=21791611; DOI=10.1128/mcb.05448-11;
RA   Yan X., Zhang J., Pan L., Wang P., Xue H., Zhang L., Gao X., Zhao X.,
RA   Ning Y., Chen Y.G.;
RT   "TSC-22 promotes transforming growth factor beta-mediated cardiac
RT   myofibroblast differentiation by antagonizing Smad7 activity.";
RL   Mol. Cell. Biol. 31:3700-3709(2011).
CC   -!- FUNCTION: Receptor-regulated SMAD (R-SMAD) that is an intracellular
CC       signal transducer and transcriptional modulator activated by TGF-beta
CC       (transforming growth factor) and activin type 1 receptor kinases. Binds
CC       the TRE element in the promoter region of many genes that are regulated
CC       by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates
CC       transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP-
CC       1/SMAD site to regulate TGF-beta-mediated transcription. Has an
CC       inhibitory effect on wound healing probably by modulating both growth
CC       and migration of primary keratinocytes and by altering the TGF-mediated
CC       chemotaxis of monocytes. This effect on wound healing appears to be
CC       hormone-sensitive. Regulator of chondrogenesis and osteogenesis and
CC       inhibits early healing of bone fractures. Positively regulates PDPK1
CC       kinase activity by stimulating its dissociation from the 14-3-3 protein
CC       YWHAQ which acts as a negative regulator (By similarity).
CC       {ECO:0000250|UniProtKB:P84022, ECO:0000269|PubMed:8917532}.
CC   -!- SUBUNIT: Monomer; in the absence of TGF-beta (By similarity).
CC       Homooligomer; in the presence of TGF-beta (By similarity).
CC       Heterotrimer; forms a heterotrimer in the presence of TGF-beta
CC       consisting of two molecules of C-terminally phosphorylated SMAD2 or
CC       SMAD3 and one of SMAD4 to form the transcriptionally active
CC       SMAD2/SMAD3-SMAD4 complex (By similarity). Part of a complex consisting
CC       of MAGI2/ARIP1, ACVR2A, ACVR1B and SMAD3 (By similarity). Forms a
CC       complex with SMAD2 and TRIM33 upon addition of TGF-beta (By
CC       similarity). Found in a complex composed of SMAD3, RAN and XPO4; within
CC       the complex interacts directly with XPO4 (By similarity). Component of
CC       the multimeric complex SMAD3/SMAD4/JUN/FOS which forms at the AP1
CC       promoter site; required for synergistic transcriptional activity in
CC       response to TGF-beta (By similarity). Part of a ternary complex
CC       composed of SMAD3, ITCH/AIP4 and NEDD9/HEF1; within the complex
CC       NEDD9/HEF1 interacts (via N-terminus) with ITCH/AIP4; the complex
CC       mediates ubiquitination and proteasomal degradation of NEDD9/HEF1 (By
CC       similarity). Interacts with NEDD9; the interaction promotes NEDD9
CC       ubiquitination and proteasomal degradation (By similarity). Interacts
CC       (via an N-terminal domain) with JUN (via its basic DNA binding and
CC       leucine zipper domains); this interaction is essential for DNA binding
CC       and cooperative transcriptional activity in response to TGF-beta (By
CC       similarity). Identified in a complex that contains at least ZNF451,
CC       SMAD2, SMAD3 and SMAD4 (By similarity). Interacts with PPM1A; the
CC       interaction dephosphorylates SMAD3 in the C-terminal SXS motif leading
CC       to disruption of the SMAD2/3-SMAD4 complex, nuclear export and
CC       termination of TGF-beta signaling (By similarity). Interacts (via MH2
CC       domain) with ZMIZ1 (via SP-RING-type domain); in the TGF-beta signaling
CC       pathway increases the activity of the SMAD3/SMAD4 transcriptional
CC       complex (By similarity). Interacts (when phosphorylated) with RNF111;
CC       RNF111 acts as an enhancer of the transcriptional responses by
CC       mediating ubiquitination and degradation of SMAD3 inhibitors (By
CC       similarity). Interacts (dephosphorylated form via the MH1 and MH2
CC       domains) with RANBP3 (via its C-terminal R domain); the interaction
CC       results in the export of dephosphorylated SMAD3 out of the nucleus and
CC       termination of the TGF-beta signaling (By similarity). Interacts (via
CC       MH2 domain) with LEMD3; the interaction represses SMAD3 transcriptional
CC       activity through preventing the formation of the heteromeric complex
CC       with SMAD4 and translocation to the nucleus (By similarity). Interacts
CC       (via the linker region) with EP300 (C-terminal); the interaction
CC       promotes SMAD3 acetylation and is enhanced by TGF-beta phosphorylation
CC       in the C-terminal of SMAD3 (By similarity). This interaction can be
CC       blocked by competitive binding of adenovirus oncoprotein E1A to the
CC       same C-terminal site on EP300, which then results in partially
CC       inhibited SMAD3/SMAD4 transcriptional activity (By similarity).
CC       Interacts with TGFBR1 (By similarity). Interacts with TGFB1I1 (By
CC       similarity). Interacts with PRDM16 (By similarity). Interacts with SNW1
CC       (By similarity). Interacts (via MH2 domain) with ZFYVE9 (By
CC       similarity). Interacts with HDAC1 (By similarity). Interacts with TGIF2
CC       (By similarity). Interacts with SKOR1 (By similarity). Interacts with
CC       SKOR2 (By similarity). Interacts with DACH1; the interaction inhibits
CC       the TGF-beta signaling (By similarity). Interacts with RBPMS (By
CC       similarity). Interacts (via MH2 domain) with MECOM (By similarity).
CC       Interacts with WWTR1 (via its coiled-coil domain) (By similarity).
CC       Interacts with SKI; the interaction represses SMAD3 transcriptional
CC       activity (By similarity). Interacts with MEN1 (PubMed:11274402).
CC       Interacts with IL1F7 (By similarity). Interaction with CSNK1G2 (By
CC       similarity). Interacts with PDPK1 (via PH domain) (By similarity).
CC       Interacts with DAB2; the interactions are enhanced upon TGF-beta
CC       stimulation (By similarity). Interacts with USP15 (By similarity).
CC       Interacts with PPP5C; the interaction decreases SMAD3 phosphorylation
CC       and protein levels (By similarity). Interacts with LDLRAD4 (via the
CC       SMAD interaction motif) (By similarity). Interacts with PMEPA1 (By
CC       similarity). Interacts with ZNF451 (By similarity). Interacts with
CC       ZFHX3 (By similarity). Interacts weakly with ZNF8 (By similarity).
CC       Interacts with STUB1, HSPA1A, HSPA1B, HSP90AA1 and HSP90AB1 (By
CC       similarity). Interacts with YAP1 (when phosphorylated at 'Ser-112') (By
CC       similarity). Interacts with MAGI2/ARIP1 (By similarity). Interacts (via
CC       MH2 domain) with CITED2 (via C-terminus) (PubMed:16619037). Interacts
CC       with HGS (By similarity). Interacts with WWP1 (By similarity).
CC       Interacts with TTRAP (By similarity). Interacts with FOXL2 (By
CC       similarity). Interacts with PML (By similarity). Interacts with NEDD4L;
CC       the interaction requires TGF-beta stimulation (By similarity).
CC       Interacts with ZC3H3 (By similarity). Interacts with TGIF. Interacts
CC       with CREBBP. Interacts with ATF2. Interacts with NEDD9; the interaction
CC       is inhibited by oxidation of NEDD9 (By similarity). Interacts with
CC       MTMR4; negatively regulates TGF-beta signaling through SMAD3
CC       dephosphorylation and retention in endosomes (By similarity).
CC       {ECO:0000250|UniProtKB:P84022, ECO:0000250|UniProtKB:Q8BUN5,
CC       ECO:0000269|PubMed:11274402, ECO:0000269|PubMed:16619037}.
CC   -!- INTERACTION:
CC       P84025; P47196: Akt1; NbExp=4; IntAct=EBI-7201857, EBI-7204362;
CC       P84025; P59595: N; Xeno; NbExp=4; IntAct=EBI-7201857, EBI-7602718;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P84022}. Nucleus
CC       {ECO:0000269|PubMed:8917532}. Note=Cytoplasmic and nuclear in the
CC       absence of TGF-beta (By similarity). On TGF-beta stimulation, migrates
CC       to the nucleus when complexed with SMAD4 (By similarity). Through the
CC       action of the phosphatase PPM1A, released from the SMAD2/SMAD4 complex,
CC       and exported out of the nucleus by interaction with RANBP1 (By
CC       similarity). Co-localizes with LEMD3 at the nucleus inner membrane.
CC       MAPK-mediated phosphorylation appears to have no effect on nuclear
CC       import (By similarity). PDPK1 prevents its nuclear translocation in
CC       response to TGF-beta (By similarity). Localized mainly to the nucleus
CC       in the early stages of embryo development with expression becoming
CC       evident in the cytoplasm of the inner cell mass at the blastocyst stage
CC       (By similarity). {ECO:0000250|UniProtKB:P84022,
CC       ECO:0000250|UniProtKB:Q8BUN5}.
CC   -!- TISSUE SPECIFICITY: Expressed in the brain (PubMed:8917532). Expressed
CC       in cardiomyocytes (PubMed:21791611). {ECO:0000269|PubMed:21791611,
CC       ECO:0000269|PubMed:8917532}.
CC   -!- DOMAIN: The MH1 domain is required for DNA binding (By similarity).
CC       Also binds zinc ions which are necessary for the DNA binding.
CC       {ECO:0000250}.
CC   -!- DOMAIN: The MH2 domain is required for both homomeric and heteromeric
CC       interactions and for transcriptional regulation. Sufficient for nuclear
CC       import (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The linker region is required for the TGFbeta-mediated
CC       transcriptional activity and acts synergistically with the MH2 domain.
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylated on serine and threonine residues. Enhanced
CC       phosphorylation in the linker region on Thr-179, Ser-204 and Ser-208 on
CC       EGF and TGF-beta treatment. Ser-208 is the main site of MAPK-mediated
CC       phosphorylation. CDK-mediated phosphorylation occurs in a cell-cycle
CC       dependent manner and inhibits both the transcriptional activity and
CC       antiproliferative functions of SMAD3. This phosphorylation is inhibited
CC       by flavopiridol. Maximum phosphorylation at the G(1)/S junction. Also
CC       phosphorylated on serine residues in the C-terminal SXS motif by TGFBR1
CC       and ACVR1. TGFBR1-mediated phosphorylation at these C-terminal sites is
CC       required for interaction with SMAD4, nuclear location and
CC       transactivational activity, and appears to be a prerequisite for the
CC       TGF-beta mediated phosphorylation in the linker region.
CC       Dephosphorylated in the C-terminal SXS motif by PPM1A. This
CC       dephosphorylation disrupts the interaction with SMAD4, promotes nuclear
CC       export and terminates TGF-beta-mediated signaling. Phosphorylation at
CC       Ser-418 by CSNK1G2/CK1 promotes ligand-dependent ubiquitination and
CC       subsequent proteasome degradation, thus inhibiting SMAD3-mediated TGF-
CC       beta responses. Phosphorylated by PDPK1 (By similarity).
CC       {ECO:0000250|UniProtKB:P84022}.
CC   -!- PTM: Acetylation in the nucleus by EP300 in the MH2 domain regulates
CC       positively its transcriptional activity and is enhanced by TGF-beta.
CC       {ECO:0000250|UniProtKB:P84022}.
CC   -!- PTM: Ubiquitinated. Monoubiquitinated, leading to prevent DNA-binding.
CC       Deubiquitination by USP15 alleviates inhibition and promotes activation
CC       of TGF-beta target genes. Ubiquitinated by RNF111, leading to its
CC       degradation: only SMAD3 proteins, that are 'in use' are targeted by
CC       RNF111, RNF111 playing a key role in activating SMAD3 and regulating
CC       its turnover. Undergoes STUB1-mediated ubiquitination and degradation.
CC       {ECO:0000250|UniProtKB:P84022, ECO:0000250|UniProtKB:Q8BUN5}.
CC   -!- PTM: Poly-ADP-ribosylated by PARP1 and PARP2. ADP-ribosylation
CC       negatively regulates SMAD3 transcriptional responses during the course
CC       of TGF-beta signaling. {ECO:0000250|UniProtKB:P84022}.
CC   -!- SIMILARITY: Belongs to the dwarfin/SMAD family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U66479; AAC52944.1; -; mRNA.
DR   EMBL; BC064437; AAH64437.1; -; mRNA.
DR   RefSeq; NP_037227.1; NM_013095.3.
DR   AlphaFoldDB; P84025; -.
DR   SMR; P84025; -.
DR   BioGRID; 247660; 3.
DR   CORUM; P84025; -.
DR   IntAct; P84025; 2.
DR   MINT; P84025; -.
DR   STRING; 10116.ENSRNOP00000037346; -.
DR   ChEMBL; CHEMBL3784913; -.
DR   iPTMnet; P84025; -.
DR   PhosphoSitePlus; P84025; -.
DR   jPOST; P84025; -.
DR   PaxDb; 10116-ENSRNOP00000037346; -.
DR   Ensembl; ENSRNOT00000039730.5; ENSRNOP00000037346.3; ENSRNOG00000008620.6.
DR   Ensembl; ENSRNOT00055040461; ENSRNOP00055032868; ENSRNOG00055023531.
DR   Ensembl; ENSRNOT00060031345; ENSRNOP00060025432; ENSRNOG00060018232.
DR   Ensembl; ENSRNOT00065012522; ENSRNOP00065009220; ENSRNOG00065007937.
DR   GeneID; 25631; -.
DR   KEGG; rno:25631; -.
DR   UCSC; RGD:3032; rat.
DR   AGR; RGD:3032; -.
DR   CTD; 4088; -.
DR   RGD; 3032; Smad3.
DR   eggNOG; KOG3701; Eukaryota.
DR   GeneTree; ENSGT00940000153499; -.
DR   HOGENOM; CLU_026736_0_0_1; -.
DR   InParanoid; P84025; -.
DR   OMA; VENCRYS; -.
DR   OrthoDB; 2891561at2759; -.
DR   PhylomeDB; P84025; -.
DR   TreeFam; TF314923; -.
DR   Reactome; R-RNO-1181150; Signaling by NODAL.
DR   Reactome; R-RNO-1502540; Signaling by Activin.
DR   Reactome; R-RNO-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-RNO-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-RNO-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-RNO-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription.
DR   Reactome; R-RNO-5689880; Ub-specific processing proteases.
DR   Reactome; R-RNO-8941855; RUNX3 regulates CDKN1A transcription.
DR   Reactome; R-RNO-9617828; FOXO-mediated transcription of cell cycle genes.
DR   PRO; PR:P84025; -.
DR   Proteomes; UP000002494; Chromosome 8.
DR   Bgee; ENSRNOG00000008620; Expressed in skeletal muscle tissue and 19 other cell types or tissues.
DR   GO; GO:0000785; C:chromatin; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0071144; C:heteromeric SMAD protein complex; ISO:RGD.
DR   GO; GO:0005637; C:nuclear inner membrane; ISO:RGD.
DR   GO; GO:0005654; C:nucleoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:CACAO.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0043235; C:receptor complex; ISO:RGD.
DR   GO; GO:0071141; C:SMAD protein complex; ISS:UniProtKB.
DR   GO; GO:0005667; C:transcription regulator complex; IDA:RGD.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL.
DR   GO; GO:0043425; F:bHLH transcription factor binding; ISO:RGD.
DR   GO; GO:0003682; F:chromatin binding; ISO:RGD.
DR   GO; GO:0031490; F:chromatin DNA binding; ISO:RGD.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0070410; F:co-SMAD binding; ISO:RGD.
DR   GO; GO:0005518; F:collagen binding; ISO:RGD.
DR   GO; GO:0017151; F:DEAD/H-box RNA helicase binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; ISO:RGD.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:RGD.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0001217; F:DNA-binding transcription repressor activity; ISO:RGD.
DR   GO; GO:0003690; F:double-stranded DNA binding; ISO:RGD.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0070411; F:I-SMAD binding; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0035259; F:nuclear glucocorticoid receptor binding; ISO:RGD.
DR   GO; GO:0031962; F:nuclear mineralocorticoid receptor binding; ISO:RGD.
DR   GO; GO:0016922; F:nuclear receptor binding; ISO:RGD.
DR   GO; GO:0019902; F:phosphatase binding; ISO:RGD.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; ISO:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; ISO:RGD.
DR   GO; GO:0070412; F:R-SMAD binding; ISO:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:RGD.
DR   GO; GO:0032810; F:sterol response element binding; ISO:RGD.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISO:RGD.
DR   GO; GO:0001223; F:transcription coactivator binding; ISO:RGD.
DR   GO; GO:0001222; F:transcription corepressor binding; ISO:RGD.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; ISO:RGD.
DR   GO; GO:0043130; F:ubiquitin binding; ISO:RGD.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:RGD.
DR   GO; GO:0008270; F:zinc ion binding; ISO:RGD.
DR   GO; GO:0032924; P:activin receptor signaling pathway; ISO:RGD.
DR   GO; GO:0030325; P:adrenal gland development; IDA:RGD.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; ISO:RGD.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0008283; P:cell population proliferation; ISO:RGD.
DR   GO; GO:0045216; P:cell-cell junction organization; ISO:RGD.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEP:RGD.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEP:RGD.
DR   GO; GO:0098586; P:cellular response to virus; ISO:RGD.
DR   GO; GO:0048589; P:developmental growth; ISO:RGD.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISO:RGD.
DR   GO; GO:0048617; P:embryonic foregut morphogenesis; ISO:RGD.
DR   GO; GO:0009880; P:embryonic pattern specification; ISO:RGD.
DR   GO; GO:0007492; P:endoderm development; ISO:RGD.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0007369; P:gastrulation; ISO:RGD.
DR   GO; GO:0001947; P:heart looping; ISO:RGD.
DR   GO; GO:0006955; P:immune response; ISO:RGD.
DR   GO; GO:0002520; P:immune system development; ISO:RGD.
DR   GO; GO:0001701; P:in utero embryonic development; ISO:RGD.
DR   GO; GO:0007254; P:JNK cascade; ISO:RGD.
DR   GO; GO:0070306; P:lens fiber cell differentiation; ISO:RGD.
DR   GO; GO:0001889; P:liver development; ISO:RGD.
DR   GO; GO:0000165; P:MAPK cascade; ISO:RGD.
DR   GO; GO:0001707; P:mesoderm formation; ISO:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:RGD.
DR   GO; GO:1903243; P:negative regulation of cardiac muscle hypertrophy in response to stress; IGI:BHF-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISO:RGD.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:RGD.
DR   GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; ISO:RGD.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0061767; P:negative regulation of lung blood pressure; IGI:BHF-UCL.
DR   GO; GO:1902894; P:negative regulation of miRNA transcription; ISO:RGD.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; ISO:RGD.
DR   GO; GO:0033689; P:negative regulation of osteoblast proliferation; ISO:RGD.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IDA:CACAO.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:RGD.
DR   GO; GO:0061045; P:negative regulation of wound healing; ISO:RGD.
DR   GO; GO:0038092; P:nodal signaling pathway; ISO:RGD.
DR   GO; GO:0002076; P:osteoblast development; ISO:RGD.
DR   GO; GO:0001649; P:osteoblast differentiation; ISO:RGD.
DR   GO; GO:0048340; P:paraxial mesoderm morphogenesis; ISO:RGD.
DR   GO; GO:0060039; P:pericardium development; ISO:RGD.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IDA:RGD.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:RGD.
DR   GO; GO:0032332; P:positive regulation of chondrocyte differentiation; ISO:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISO:RGD.
DR   GO; GO:1901203; P:positive regulation of extracellular matrix assembly; ISO:RGD.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IDA:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; IMP:RGD.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; ISO:RGD.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IGI:BHF-UCL.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:RGD.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IDA:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:RGD.
DR   GO; GO:0032916; P:positive regulation of transforming growth factor beta3 production; IMP:RGD.
DR   GO; GO:0050821; P:protein stabilization; IMP:BHF-UCL.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0050678; P:regulation of epithelial cell proliferation; ISO:RGD.
DR   GO; GO:0050776; P:regulation of immune response; ISO:RGD.
DR   GO; GO:0016202; P:regulation of striated muscle tissue development; ISO:RGD.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; ISO:RGD.
DR   GO; GO:0032909; P:regulation of transforming growth factor beta2 production; ISO:RGD.
DR   GO; GO:1990776; P:response to angiotensin; ISO:RGD.
DR   GO; GO:0001666; P:response to hypoxia; ISO:RGD.
DR   GO; GO:0071559; P:response to transforming growth factor beta; ISO:RGD.
DR   GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0001501; P:skeletal system development; ISO:RGD.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IMP:BHF-UCL.
DR   GO; GO:0001756; P:somitogenesis; ISO:RGD.
DR   GO; GO:0042110; P:T cell activation; ISO:RGD.
DR   GO; GO:0030878; P:thyroid gland development; ISO:RGD.
DR   GO; GO:0060290; P:transdifferentiation; IDA:RGD.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0001657; P:ureteric bud development; ISO:RGD.
DR   CDD; cd10491; MH1_SMAD_2_3; 1.
DR   CDD; cd10985; MH2_SMAD_2_3; 1.
DR   Gene3D; 2.60.200.10; -; 1.
DR   Gene3D; 3.90.520.10; SMAD MH1 domain; 1.
DR   InterPro; IPR013790; Dwarfin.
DR   InterPro; IPR003619; MAD_homology1_Dwarfin-type.
DR   InterPro; IPR013019; MAD_homology_MH1.
DR   InterPro; IPR017855; SMAD-like_dom_sf.
DR   InterPro; IPR001132; SMAD_dom_Dwarfin-type.
DR   InterPro; IPR008984; SMAD_FHA_dom_sf.
DR   InterPro; IPR036578; SMAD_MH1_sf.
DR   PANTHER; PTHR13703:SF53; MOTHERS AGAINST DECAPENTAPLEGIC HOMOLOG 3; 1.
DR   PANTHER; PTHR13703; SMAD; 1.
DR   Pfam; PF03165; MH1; 1.
DR   Pfam; PF03166; MH2; 1.
DR   SMART; SM00523; DWA; 1.
DR   SMART; SM00524; DWB; 1.
DR   SUPFAM; SSF56366; SMAD MH1 domain; 1.
DR   SUPFAM; SSF49879; SMAD/FHA domain; 1.
DR   PROSITE; PS51075; MH1; 1.
DR   PROSITE; PS51076; MH2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ADP-ribosylation; Cytoplasm; Isopeptide bond; Metal-binding;
KW   Nucleus; Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P84022"
FT   CHAIN           2..425
FT                   /note="Mothers against decapentaplegic homolog 3"
FT                   /id="PRO_0000090859"
FT   DOMAIN          10..136
FT                   /note="MH1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00438"
FT   DOMAIN          232..425
FT                   /note="MH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00439"
FT   REGION          137..231
FT                   /note="Linker"
FT   REGION          165..208
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          271..324
FT                   /note="Sufficient for interaction with XPO4"
FT                   /evidence="ECO:0000250"
FT   BINDING         64
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         109
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         121
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         126
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   SITE            40
FT                   /note="Required for trimerization"
FT                   /evidence="ECO:0000250"
FT   SITE            41
FT                   /note="Required for interaction with DNA and JUN and for
FT                   functional cooperation with JUN"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:P84022"
FT   MOD_RES         8
FT                   /note="Phosphothreonine; by CDK2 and CDK4"
FT                   /evidence="ECO:0000250|UniProtKB:P84022"
FT   MOD_RES         179
FT                   /note="Phosphothreonine; by CDK2, CDK4 and MAPK"
FT                   /evidence="ECO:0000250|UniProtKB:P84022"
FT   MOD_RES         204
FT                   /note="Phosphoserine; by GSK3 and MAPK"
FT                   /evidence="ECO:0000250|UniProtKB:P84022,
FT                   ECO:0000255|PROSITE-ProRule:PRU00439"
FT   MOD_RES         208
FT                   /note="Phosphoserine; by MAPK"
FT                   /evidence="ECO:0000250|UniProtKB:P84022,
FT                   ECO:0000255|PROSITE-ProRule:PRU00439"
FT   MOD_RES         213
FT                   /note="Phosphoserine; by CDK2 and CDK4"
FT                   /evidence="ECO:0000250|UniProtKB:P84022,
FT                   ECO:0000255|PROSITE-ProRule:PRU00439"
FT   MOD_RES         378
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P84022"
FT   MOD_RES         416
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P84022,
FT                   ECO:0000255|PROSITE-ProRule:PRU00439"
FT   MOD_RES         418
FT                   /note="Phosphoserine; by CK1"
FT                   /evidence="ECO:0000250|UniProtKB:P84022,
FT                   ECO:0000255|PROSITE-ProRule:PRU00439"
FT   MOD_RES         422
FT                   /note="Phosphoserine; by TGFBR1"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BUN5,
FT                   ECO:0000255|PROSITE-ProRule:PRU00439"
FT   MOD_RES         423
FT                   /note="Phosphoserine; by TGFBR1"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BUN5,
FT                   ECO:0000255|PROSITE-ProRule:PRU00439"
FT   MOD_RES         425
FT                   /note="Phosphoserine; by TGFBR1"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BUN5,
FT                   ECO:0000255|PROSITE-ProRule:PRU00439"
FT   CROSSLNK        33
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P84022"
FT   CROSSLNK        81
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P84022"
SQ   SEQUENCE   425 AA;  48081 MW;  46DF5E8B371321AC CRC64;
     MSSILPFTPP IVKRLLGWKK GEQNGQEEKW CEKAVKSLVK KLKKTGQLDE LEKAITTQNV
     NTKCITIPRS LDGRLQVSHR KGLPHVIYCR LWRWPDLHSH HELRAMELCE FAFNMKKDEV
     CVNPYHYQRV ETPVLPPVLV PRHTEIPAEF PPLDDYSHSI PENTNFPAGI EPQSNIPETP
     PPGYLSEDGE TSDHQMNHSM DAGSPNLSPN PMSPAHNNLD LQPVTYCEPA FWCSISYYEL
     NQRVGETFHA SQPSMTVDGF TDPSNSERFC LGLLSNVNRN AAVELTRRHI GRGVRLYYIG
     GEVFAECLSD SAIFVQSPNC NQRYGWHPAT VCKIPPGCNL KIFNNQEFAA LLAQSVNQGF
     EAVYQLTRMC TIRMSFVKGW GAEYRRQTVT STPCWIELHL NGPLQWLDKV LTQMGSPSIR
     CSSVS
//
